에 대한 최신 뉴스 AmpliTech Group (NASDAQ:AMPG) 주식

AmpliTech Gr

AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.

AmpliTech Group Inc

JP Morgan analyst Bill Peterson downgraded United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) from Overweight to Neutral and cut the price <a target="_blank" href="https://www.benzinga.com/quote/x/analyst-ratings" rel="noreferrer noopener">forecast from $43 to $38</a>.
The analyst cited the pending NSC deal, which seems to be &#8216;in the hands <a target="_blank" href="https://in.benzinga.com/25/03/44545889/nippon-attempts-to-revive-us-steel-deal-with-larger-capital-investments" rel="noreferrer noopener">of the Trump administration&#8217; as the reason</a>.
In recent news, Nippon Steel&nbsp;and&nbsp;United States Steel&nbsp;are reportedly negotiating with the Trump administration to revive their $14 billion merger by significantly boosting investments in U.S. Steel&#8217;s <a target="_blank" href="https://www.benzinga.com/news/guidance/25/03/44432858/us-steel-faces-q1-pressures-but-eyes-long-term-gains-from-br2-nippon-partnership" rel="noreferrer noopener">Rust Belt facilities.</a>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44733757/trump-torpedoes-us-steel-deal-x-stock-tumbles-despite-bullish-chart" rel="noreferrer noopener">Trump Torpedoes US Steel Deal, X Stock Tumbles Despite Bullish Chart</a>
The analyst writes that, on the demand side, construction is under pressure, while tin/container demand should benefit from S232 tariffs.
Meanwhile, Peterson believes that the auto sector may experience short-term demand pull-through from earlier pre-buying, with longer-term tariff risks potentially impacting demand.
Regarding BRS2&#8217;s ramp-up, the analyst expects upstream melt capacity to be fully online in the second half of 2025, with the entire facility reaching steady-state production by 2026.
The analyst notes that last month, the company guided for the first quarter of 2025 adjusted EPS loss of 53 cents–49 cents (vs.&nbsp;consensus loss of 30 cents) and adjusted EBITDA of about $125 million, in line with <a target="_blank" href="https://www.benzinga.com/news/guidance/25/03/44432858/us-steel-faces-q1-pressures-but-eyes-long-term-gains-from-br2-nippon-partnership" rel="noreferrer noopener">prior&nbsp;outlook of&nbsp;$100 million&nbsp;– $150 million</a>.
Consequently, Peterson now estimates softer FRP shipments this year and flat next year (-0.9%/+0.4% vs. previous +0.1%/+0.0%) to account for auto tariff risks.
Investors can gain exposure to the stock via&nbsp;VanEck Steel ETF&nbsp;(NYSE:<a target="_blank" href="https://www.benzinga.com/stock/SLX#NYSE" rel="noreferrer noopener"> SLX</a>) and&nbsp;SPDR S&amp;P Metals &amp; Mining ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XME#NYSE">XME</a>).
Price Action: United States Steel shares are up 0.65% at $41.66 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44727180" target="_blank" rel="noreferrer noopener">Cramer Praises Trump For Pushback On Nippon &#8216;Dumper&#8217; Steel, Calls The Block A &#8216;Smart Move&#8217;</a></li>
</ul>
Photo by T. Schneide via Shutterstock

Analyst Color

Equities

Large Cap

News

Downgrades

Price Target

Analyst Ratings

Trading Ideas

With Nippon Deal In Trump's Court, JPMorgan Turns Cautious On US Steel

WIIM

LRHC

La Rosa Holdings shares are trading lower. The company reported FY24 financial results.

<a href="https://www.nytimes.com/2025/04/16/technology/nvidia-deepseek-china-ai-trump.html" title="https://www.nytimes.com/2025/04/16/technology/nvidia-deepseek-china-ai-trump.html">https://www.nytimes.com/2025/04/16/technology/nvidia-deepseek-china-ai-trump.html</a>

Macro Economic Events

Global

Economics

NVDA

NYT Reports Trump Admin Is 'weighing penalties that would block DeepSeek from buying U.S. technology and debating barring Americans' access to its services'

SUNE

SUNation Energy shares are trading lower after the company announced a 1-for-200 reverse stock split.

GRRR

Gorilla Technology Group shares are trading lower. The company announced it's suing Culper Research for defamation and alleges their short report was false and malicious.

Citigroup analyst Scott Gruber maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Neutral and lowers the price target from $20 to $15.

Citigroup Maintains Neutral on APA, Lowers Price Target to $15

Federal Reserve

Powell On Tariffs Says Job Is To Make Sure This Is Not Something That Turns Into An Ongoing Inflation Process

PERI

Perion Network shares are trading higher after the company issued Q1 revenue guidance above estimates.

Fed Chair Powell Says Tariffs Larger Even Than In Fed's Upside Estimates

DOMO

Domo shares are trading lower after Morgan Stanley cut its price target on the stock from $9 to $8.

Raymond James analyst Srini Pajjuri maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Strong Buy and lowers the price target from $170 to $150.

Raymond James Maintains Strong Buy on NVIDIA, Lowers Price Target to $150

Raymond James analyst Jayson Bedford maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and raises the price target from $162 to $164.

Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to $164

Lake Street analyst Eric Martinuzzi maintains TechTarget (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTGT#NASDAQ">TTGT</a>) with a Buy and lowers the price target from $24 to $12.

TTGT

Lake Street Maintains Buy on TechTarget, Lowers Price Target to $12

Loop Capital analyst Anthony Chukumba maintains Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) with a Buy and lowers the price target from $150 to $120.

SHOP

Loop Capital Maintains Buy on Shopify, Lowers Price Target to $120

Raymond James analyst Michael Rose reiterates Hancock Whitney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWC#NASDAQ">HWC</a>) with a Strong Buy and lowers the price target from $72 to $62.

Reiteration

Raymond James Reiterates Strong Buy on Hancock Whitney, Lowers Price Target to $62

Powell Says 'strong imports during the first quarter, reflecting attempts by businesses to get ahead of potential tariffs, are expected to weigh on GDP growth.'

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower, falling amid prepared remarks from Fed Chair Powell at the Economic Club of Chicago. Additionally, weakness in chips stocks is weighing on markets after NVIDIA said it was recently informed by the US government that it will need a license to export chips to China.

Last week, U.S.&nbsp;President&nbsp;Donald Trump disclosed plans for a &#8220;major tariff&#8221; on&nbsp;<a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noreferrer noopener">foreign pharmaceuticals</a>.
BofA Securities&nbsp;analyst said if the Trump administration plans to impose tariffs on the pharmaceutical industry, it would likely do so through a &#8220;Section 232 investigation&#8221; under the Trade Expansion Act of 1962 to determine whether importing certain goods threatens national security.
The U.S. Department of Commerce has launched an investigation into the potential national security risks posed by the country&#8217;s reliance on imported pharmaceuticals and key drug ingredients.
The probe, initiated under Section 232 of the Trade Expansion Act, will examine the effects of these imports on the nation&#8217;s ability to produce essential medicines and respond to public health emergencies.
Announced on April 1, 2025, the investigation will evaluate a wide scope of pharmaceutical imports.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
This includes finished generic and non-generic drug products, medical countermeasures, active pharmaceutical ingredients (APIs), key starting materials (KSMs) and related derivative products.
The <a target="_blank" href="https://public-inspection.federalregister.gov/2025-06587.pdf" rel="noreferrer noopener">goal</a> is to assess how these imports affect the integrity and resilience of the domestic pharmaceutical supply chain.
The Bureau of Industry and Security (BIS) is seeking input from stakeholders as part of the investigation.
As per the Federal Register filing, key issues under review include current and future U.S. demand for pharmaceutical products and whether domestic manufacturing capacity can meet that demand.
There will be an examination of the role of foreign supply chains, particularly the extent to which U.S. pharmaceutical imports are concentrated among a small number of suppliers and the associated risks of such dependence.
Additional focus areas include the impact of foreign subsidies and potentially predatory trade practices on the competitiveness of U.S. pharmaceutical companies.
The department is also looking into concerns over artificially suppressed prices due to foreign state-sponsored overproduction and the risk of export restrictions by foreign governments that could be used to leverage geopolitical power.
The feasibility of expanding domestic manufacturing capacity to reduce reliance on imports and the effectiveness of current trade policies will also be evaluated.
The investigation could result in policy recommendations, including potential tariffs or quotas, to bolster the nation&#8217;s pharmaceutical security.
"AAM and the generics and biosimilars industry look forward to working with the Commerce Department and the White House to engage constructively on ways to incent more domestic investment in the medicines supply chain," <a href="https://accessiblemeds.org/resources/press-releases/aam-comments-on-section-232-investigation-on-pharmaceuticals/" target="_blank" rel="noreferrer noopener">said</a> John Murphy III, president and CEO of the Association for Accessible Medicines, a trade association representing the manufacturers and distributors of generic prescription drugs.
&#8220;Tariffs, however, will only amplify the problems that already exist in the U.S. market for affordable medicines,&#8221; Murphy added.
"Without substantive regulatory and reimbursement changes to the U.S. market, tariffs will exacerbate shortages that hinder patient access today," he continued.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44841871/lyft-expands-to-europe-with-e175m-freenow-acquisition-targets-bookings-by-e1b-annually" target="_blank" rel="noreferrer noopener">BMW, Mercedes-Benz Sell Taxi App To Lyft For $197M: CEO Says Entering Europe Is &#8216;Important Step&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Aria+Armoko">Aria Armoko</a> via Shutterstock

Biotech

Government

Regulations

Health Care

Legal

General

Trump Administration Opens Probe Into Foreign Drug Imports, Eyes Tariffs Under National Security Law

Markets

S&P Drops Amid Prepared Remarks From Powell At Economic Club of Chicago

Barclays analyst Christine Cho maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Overweight and lowers the price target from $86 to $58.

ENPH

Barclays Maintains Overweight on Enphase Energy, Lowers Price Target to $58

Press Releases

CORRECTION -- AmpliTech Group's 5G Division Receives Initial Order For Three Configurations Of The Company's Suite of 5G ORAN Radios

AmpliTech Group Announces Over $2.1M in New Purchase Orders in Q1, All Set for Delivery in Fiscal Year 2025

AmpliTech Group's Recently Issued Patents Valued at $14.9 Million by ipCapital Group

AmpliTech Group Announces Innovative True 5G Technology Development

Contracts

AmpliTech Group Announces Initial Order For Flagship ORAN 64T64R MIMO Radio

AmpliTech Group's 5G Division Enters Into An LOI For US$78 Million In Purchase Orders For AmpliTech's 5G ORAN Radios

AmpliTech Group Secures Major Milestone: Receives Initial Purchase Order from Leading 5G ORAN Player Marking Beginning Of US$78M Announced LOI

Earnings

AmpliTech Reports FY 2024 Financial Results

AmpliTech Group, Inc. Highlights "Made in the USA" Products Amidst Booming Industry Growth and Global Trade Tensions

AmpliTech Group's 5G Division Secures Company-Record Approx. US$11 Million Purchase Orders As Part Of A New Multi-Year LOI From Tier 1 North American MNO

Comments

AmpliTech Group

뉴스

에 대한 최신 뉴스 AmpliTech Group (NASDAQ:AMPG) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌